Determination of Rates and Reasons for Non-Adherence to Anti-Arrhythmic Therapy for Atrial Fibrillation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01513031|
Recruitment Status : Terminated (Low enrollment)
First Posted : January 20, 2012
Last Update Posted : July 2, 2012
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation Medication Adherence||Other: Education and telephone follow-up||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Pilot Project to Determine Rates and Reasons for Non-Adherence in Patients Receiving Chronic Oral Antiarrhythmic Therapy for Atrial Fibrillation in the State of Nebraska|
|Study Start Date :||January 2012|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||June 2012|
Experimental: Phone follow-up
All study participants will be receiving education and monthly telephone follow-up.
Other: Education and telephone follow-up
Education related to anti-arrhythmic therapy and monthly telephone follow-up to assess adherence to medication.
- Adherence to anti-arrhythmic medication [ Time Frame: 1 year ]Assessing whether patients stop taking anti-arrhythmic medication without instruction to do so by their physician.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01513031
|United States, Nebraska|
|Lincoln, Nebraska, United States, 68506|
|Alegent Health Bergan Mercy Medical Center|
|Omaha, Nebraska, United States, 68124|
|Omaha, Nebraska, United States, 68178|
|Principal Investigator:||Dan Hilleman, PharmD||Creighton University|